Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition ...

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.

There have been limited advancements for treating pancreatic cancer, and chemotherapy has been the standard of care for more than 30 years. About Arcus Biosciences Arcus Biosciences is a ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. (2009) 16:1727–33. doi: 10.1245/s10434-009-0408-6 ...

Pancreatic cancer remains a highly aggressive malignancy with limited treatment options, especially in its resectable form.

Seven warning signs of pancreatic cancer you shouldn't ignore as these subtle symptoms often get dismissed but could save your life ...

MRI-based screening has the potential for identifying early-stage pancreatic cancer in older adults with new onset or deteriorating diabetes, preliminary results show.

Regular screening can bend the odds in your favor when it comes to four types of cancers. The science is less clear for the rest.